Sarah Howell, Ph.D., Chief Executive Officer and Executive Director
Sarah Howell was appointed Chief Executive Officer of Arecor in 2015, having joined in 2011 as Chief Operating Officer and Executive Director.
Susan Lowther, Chief Financial Officer and Executive Director/Company Secretary
Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019. She brings significant financial leadership experience across a broad range of public and private life science companies.
Jan Jezek, Ph.D., Chief Scientific Officer
Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat™ platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.
Manjit Rahelu, Ph.D., Chief Business Officer
Manjit is an accomplished strategic deal maker, with a strong scientific background and over 25 years of technical, commercial and financial experience across large and mid-sized pharmaceutical and biotechnology companies.
David Gerring, Senior VP, Development
David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.